2,2-二甲基-6-硝基-3,4-二氢色烯-4-醇 | 153121-40-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 中文名称: 2,2-二甲基-6-硝基-3,4-二氢色烯-4-醇
• 英文名称: 2,2-dimethyl-6-nitrochroman-4-ol
• 英文别名: 2,2-Dimethyl-6-nitro-3,4-dihydro-2H-1-benzopyran-4-ol；2,2-dimethyl-6-nitro-3,4-dihydrochromen-4-ol
• CAS: 153121-40-5
• 化学式: C₁₁H₁₃NO₄
• 分子量: 223.229
• InChiKey: OIWOLPHHMJJREU-UHFFFAOYSA-N

物化性质

• 沸点：
  345.6±42.0 °C(Predicted)
• 密度：
  1.278±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  75.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,2-二甲基-6-硝基-3,4-二氢色烯-4-醇 在 铁粉 、 氯化铵 、 对甲苯磺酸 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 反应 8.0h， 生成 2,2-dimethyl-2H-chromen-6-amine
  参考文献：
  名称：

  N-(2,7-二甲基-2-烷基-2H-chromen-6-yl) 磺酰胺衍生物作为选择性血清素 5-HT6 受体拮抗剂：设计、合成和生物学评价

  摘要：

  主要在中枢神经系统中表达的血清素 5-HT 6受体是一种有价值的治疗靶点。5-羟色胺 5-HT 6受体拮抗剂具有治疗各种疾病的潜力，包括精神病、痴呆、抑郁和肥胖。在这项研究中，我们设计并合成了基于N- (2,7-二甲基-2-烷基-2 H -chromen-6- yl ) 磺酰胺的文库，作为潜在的 5-羟色胺 5-HT 6受体拮抗剂。对该文库进行一系列结合亲和力测试以鉴定先导化合物，并检查测试化合物对 5-HT 6受体的选择性。因此，复合6m被鉴定为活性最强的化合物，IC50 = 87 nM。的95.3％的结合亲和力6米（10μM）与5-HT 6除其他血清素5-HT受体1A，5-HT 2A，5-HT 2C和5-HT 7，和多巴胺受体ð 1，d图2、D 3和D 4证明了6m对5-HT 6受体的高选择性。

  DOI：

  10.1016/j.molstruc.2021.131417
• 作为产物：
  描述：

  4-硝基苯基乙酸酯 在 四氢吡咯 、 aluminum (III) chloride 、 sodium tetrahydroborate 作用下， 以 甲醇 、 甲苯 为溶剂， 反应 4.0h， 生成 2,2-二甲基-6-硝基-3,4-二氢色烯-4-醇
  参考文献：
  名称：

  Identification of 3-hydroxy-4[3,4-dihydro-3-oxo-2H-1,4-benzoxazin-4-yl]-2,2-dimethyldihydro-2H-benzopyran derivatives as potassium channel activators and anti-inflammatory agents

  摘要：

  The present study described the design, synthesis and identification of 3-hydroxy-4[3,4-dihydro-3-oxo-2H-1,4-benzoxazin-4-yl]-2,2-dimethyldihydro-2H-benzopyran derivatives. Their biological activity was tested for K-ATP channel opener as antihypertensives, COX-1 and COX-2 activity. The results were compared with the activity of cromakalim, ibuprofen and celecoxib. The study aimed at exploring the influence of introduction of a benzoxazine substituent at position 6 of various derivatives of benzopyrans in order to improve biological activity. Several compounds were found to be equipotent or even more potent than cromakalim. Out of these nitro-substituted benzopyrans, nitro substitution at benzoxazino group possessed potent antihypertensive activity in the R/S isomers. With amino derivatives, activity remains constant when compared with standard cromakalim. Similarly, compounds 17b, 17c, 17e and 17h have exhibited around 40 % inhibition of COX-1 as compared to the inhibition of COX-2. Only two compounds 17g and 17i exhibited effective inhibition more than 50 % of COX-2 compared with the inhibition of COX-1 at a concentration of 0.3 mg/ml.

  DOI：

  10.1007/s00044-015-1344-6

文献信息

• N-(2,7-dimethyl-2-alkyl-2H-chromen-6-yl)sulfonamide derivatives as selective serotonin 5-HT6 receptor antagonists: Design, synthesis, and biological evaluation
  作者：Aizhan Abdildinova、Young Chang Kim、Gee-Hyung Lee、Woo-Kyu Park、Heeyeong Cho、Young-Dae Gong

  DOI：10.1016/j.molstruc.2021.131417

  日期：2022.1

  a potential serotonin 5-HT6 receptor antagonist. The library was subjected to a series of binding affinity tests to identify the lead compound, and check the selectivity of test compounds towards the 5-HT6 receptor. Accordingly, compound 6m was identified as the most active compound, with IC50 = 87 nM. The binding affinity of 95.3% of 6m (10 μM) with the 5-HT6 receptor among other serotonin 5-HT1a,

  主要在中枢神经系统中表达的血清素 5-HT 6受体是一种有价值的治疗靶点。5-羟色胺 5-HT 6受体拮抗剂具有治疗各种疾病的潜力，包括精神病、痴呆、抑郁和肥胖。在这项研究中，我们设计并合成了基于N- (2,7-二甲基-2-烷基-2 H -chromen-6- yl ) 磺酰胺的文库，作为潜在的 5-羟色胺 5-HT 6受体拮抗剂。对该文库进行一系列结合亲和力测试以鉴定先导化合物，并检查测试化合物对 5-HT 6受体的选择性。因此，复合6m被鉴定为活性最强的化合物，IC50 = 87 nM。的95.3％的结合亲和力6米（10μM）与5-HT 6除其他血清素5-HT受体1A，5-HT 2A，5-HT 2C和5-HT 7，和多巴胺受体ð 1，d图2、D 3和D 4证明了6m对5-HT 6受体的高选择性。
• Identification of 3-hydroxy-4[3,4-dihydro-3-oxo-2H-1,4-benzoxazin-4-yl]-2,2-dimethyldihydro-2H-benzopyran derivatives as potassium channel activators and anti-inflammatory agents
  作者：Mohsina Bano、Kuldipsinh P. Barot、Shailesh V. Jain、Manjunath D. Ghate

  DOI：10.1007/s00044-015-1344-6

  日期：2015.7

  The present study described the design, synthesis and identification of 3-hydroxy-4[3,4-dihydro-3-oxo-2H-1,4-benzoxazin-4-yl]-2,2-dimethyldihydro-2H-benzopyran derivatives. Their biological activity was tested for K-ATP channel opener as antihypertensives, COX-1 and COX-2 activity. The results were compared with the activity of cromakalim, ibuprofen and celecoxib. The study aimed at exploring the influence of introduction of a benzoxazine substituent at position 6 of various derivatives of benzopyrans in order to improve biological activity. Several compounds were found to be equipotent or even more potent than cromakalim. Out of these nitro-substituted benzopyrans, nitro substitution at benzoxazino group possessed potent antihypertensive activity in the R/S isomers. With amino derivatives, activity remains constant when compared with standard cromakalim. Similarly, compounds 17b, 17c, 17e and 17h have exhibited around 40 % inhibition of COX-1 as compared to the inhibition of COX-2. Only two compounds 17g and 17i exhibited effective inhibition more than 50 % of COX-2 compared with the inhibition of COX-1 at a concentration of 0.3 mg/ml.